Leerink Swann Downgrades Omthera Pharmaceuticals (OMTH) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Stifel Nicolaus Downgrades Omthera Pharmaceuticals (OMTH) to Hold
May 29, 2013 6:42 AM EDTStifel Nicolaus downgraded Omthera Pharmaceuticals (NASDAQ: OMTH) from Buy to Hold.
For an analyst ratings summary and ratings history on Omthera Pharmaceuticals click here. For more ratings news on Omthera Pharmaceuticals click here.
Shares of Omthera Pharmaceuticals closed at $13.51 yesterday, with a 52 week range of $5.69-$13.75.... More
Piper Jaffray Downgrades Omthera Pharmaceuticals (OMTH) to Neutral
May 28, 2013 11:09 AM EDTPiper Jaffray downgraded Omthera Pharmaceuticals (NASDAQ: OMTH) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Omthera Pharmaceuticals click here. For more ratings news on Omthera Pharmaceuticals click here.
Shares of Omthera Pharmaceuticals closed at $6.77 yesterday, with a 52 week range of $5.69-$7.90.... More
Omthera Pharmaceut (OMTH) Posts Q1 Loss of $3.08/Share
May 28, 2013 9:25 AM EDTOmthera Pharmaceut (NASDAQ: OMTH) reported Q1 EPS of ($3.08), $0.77 worse than the analyst estimate of ($2.31).
For earnings history and earnings-related data on Omthera Pharmaceut (OMTH) click here.... More
AstraZeneca (AZN) to Acquire Omthera (OMTH) for $12.70/Share
May 28, 2013 6:05 AM EDTAstraZeneca (NYSE: AZN) announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals (Nasdaq: OMTH), a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialisation of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Omtheras investigational product, EpanovaTM, for the potential treatment of patients with very high triglycerides, is a novel omega-3 free fatty acid composition that has been shown to bolster levels of eicosapentaenoic acid and docosahexaenoic acid... More
